The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function

Cancer

Volumn 116, Issue 16, 2010, Pages 3807-3814

  Dimopoulos, Meletios ^a   Alegre, Adrian ^b   Stadtmauer, Edward A ^c   Goldschmidt, Hartmut ^d   Zonder, Jeffrey A ^e   De Castro, Carlos M ^f   Masliak, Zvenyslava ^g   Reece, Donna ^h   Olesnyckyj, Marta ⁱ   Yu, Zhinuan ⁱ   Weber, Donna M ^j  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e WAYNE STATE UNIVERSITY   (United States)

^f DUKE UNIVERSITY MEDICAL CENTER   (United States)

^g Hematology Department of the Academy of Medical Sciences of Ukraine   (Ukraine)

^h PRINCESS MARGARET HOSPITAL   (Canada)

ⁱ CELGENE CORPORATION   (United States)

^j UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

more..

Author keywords

Creatinine clearance; Dexamethasone; Lenalidomide; Multiple myeloma; Renal impairment

Indexed keywords

CREATININE; DEXAMETHASONE; LENALIDOMIDE; ANTINEOPLASTIC AGENT; THALIDOMIDE;

ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; CANCER GROWTH; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DEHYDRATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; HYPOCALCEMIA; KIDNEY FAILURE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; NEUROPATHY; NEUTROPENIA; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; COMPLICATION; DISEASE FREE SURVIVAL; DRUG RESISTANCE; IN VITRO STUDY; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOPHYSIOLOGY; RECURRENT DISEASE; RENAL INSUFFICIENCY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEXAMETHASONE; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MIDDLE AGED; MULTIPLE MYELOMA; RECURRENCE; RENAL INSUFFICIENCY; THALIDOMIDE; IN VITRO TECHNIQUES;

EID: 77953862198     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25139     Document Type: Article

References (21)

1. Dimopoulos MA, Kastritis E, Rosinol L, Bladé J, Ludwig H. Pathogenesis and treatment of renal failure in multiple myeloma. Leukemia. 2008;22:1485-1493.
2. Herrera GA, Joseph L, Gu X, Hough A, Barlogie B. Renal pathologic spectrum in an autopsy series of patients with plasma cell dyscrasia. Arch Pathol Lab Med. 2004;128:875-879.
3. Korbet SM, Schwartz MM. Multiple myeloma. J Am Soc Nephrol. 2006;17:2533-2545.
4. Bladé J, Fernández-Llama P, Bosch F, et al. Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med. 1998;158:1889-1893.
5. Knudsen LM, Hippe E, Hjorth M, Holmberg E, Westin J. Renal function in newly diagnosed multiple myeloma - a demographic study of 1353 patients. The Nordic Myeloma Study Group. Eur J Haematol. 1994;53:207-212.
6. Knudsen LM, Hjorth M, Hippe E. Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic Myeloma Study Group. Eur J Haematol. 2000;65:175-181.
7. Eleutherakis-Papaiakovou V, Bamias A, Gika D, et al; Greek Myeloma Study Group. Renal failure in multiple myeloma: incidence, correlations, and prognostic significance. Leuk Lymphoma. 2007;48:337-341.
8. Bladé J, Rosiñol L. Renal, hematologic and infectious complications in multiple myeloma. Best Pract Res Clin Haematol. 2005;18:635-652.
9. Kastritis E, Anagnostopoulos A, Roussou M, et al. Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents. Haematologica. 2007;92:546-549.
10. Carlson K, Hjorth M, Knudsen LM; Nordic Myeloma Study Group. Toxicity in standard melphalan-prednisone therapy among myeloma patients with renal failure - a retrospective analysis and recommendations for dose adjustment. Br J Haematol. 2005;128:631-635.
11. Nozza A, Siracusano L, Armando S. Bortezomib-dexamethasone combination in a patient with refractory multiple myeloma and impaired renal function. Clin Ther. 2006;28:953-959.
12. Weber DM, Chen C, Niesvizky R, et al; Multiple Myeloma (009) Study Investigators. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. 2007;357:2133-2142.
13. Dimopoulos M, Spencer A, Attal M, et al; Multiple Myeloma (010) Study Investigators. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007;357:2123-2132.
14. Chen N, Lau H, Kong L, et al. Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis. J Clin Pharmacol. 2007;47:1466-1475.
15. Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL, eds. Harrison's Principles of Internal Medicine, 16th ed. New York: McGraw-Hill, Medical Publishing Division; 2005.
16. Bladé J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol. 1998;102:1115-1123.
17. Durie BG, Harousseau JL, Miguel JS, et al; International Myeloma Working Group. International uniform response criteria for multiple myeloma. Leukemia. 2006;20:1467-1473.
18. Augustson BM, Begum G, Dunn JA, et al. Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United Kingdom Medical Research Council trials between 1980 and 2002 - Medical Research Council Adult Leukaemia Working Party. J Clin Oncol. 2005;23:9219-9226.
19. Darmon M, Ciroldi M, Thiery G, Schlemmer B, Azoulay E. Clinical review: specific aspects of acute renal failure in cancer patients [serial online]. Crit Care. 2006;10:211.
20. Celgene Corporation. REVLIMID (lenalidomide) Product Information. Summit, NJ: Celgene Corporation; 2009.
21. Celgene Corporation. REVLIMID (lenalidomide) Product Information. Celgene Europe Limited. Berkshire, United Kingdom: Celgene Europe Ltd.; 2009. Available at: http://emc.medicines.org.uk/printfriendlydocument.aspx?documentid= 19841&companyid=1868. Accessed April 6, 2009.